Ayalew Tefferi MD on Imetelstat as Therapy for Myelofibrosis

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementation of a Heparin-Induced Thrombocytopenia Management Program Reduces the Cost of Diagnostic Testing and Pharmacologic Treatment in an Academic Medical Center,” presented by Caroline Dupre Vaughn, RN.

Hematologic Malignancies

Linda J. Burns, MD

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53, “ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults With Beta-Thalassemia: Preliminary Results From a Phase II Study,” presented by Antonio G. Piga, MD.

Leukemia

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

James. O Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discuss advances in treating acute myeloid leukemia and the acute promyelocytic leukema subtype.

Lymphoma

Laurie Sehn, MD

Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multicenter Phase II Study Report,” presented by Jia Ruan, MD, PhD.

Leukemia

Linda J. Burns, MD

Linda J. Burns, MD, on the BLAST Study

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL),” presented by Nicola Gökbuget, MD.

Time: 1:11

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Related Videos

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma

Linda J. Burns, MD, on the BLAST Study

FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer

MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer

Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy

Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma

Microplastics Found in 90 Percent of Prostate Cancer Samples